Resident Time in Joint

DUROLANE was shown to have a half-life of 4 weeks or 32 days in the joint following a single injection.3,6

DUROLANE has a longer half-life than cross-linked and unstabilized hylan G-F 20 (Synvisc® and Synvisc-One®).4,5

Graphs based on elimination of hyaluronic acid (HA) from the joint space of rabbits as a function of time for DUROLANE6 as compared against extrapolated data for the residence time of hylan G-F 204 and low molecular weight HA5 in a similar rabbit model. DUROLANE values calculated based on projected clearance of one-3 mL injection (20 mg/mL). Hylan G-F 20 values calculated based on projected clearance of one-6 mL injection (representing Synvisc-One®) or three-2.0 mL injections (representing Synvisc-3 injection regimen) of HA at 16 mg/mL in a rabbit model.4 As shown in the graph, DUROLANE human data correlates well with the rabbit model.3

Summary of Indications for UseDUROLANE (3mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

Our website uses cookies, some of which are essential for this site to operate correctly and have already been set. For more information on managing, blocking or deleting cookies within your browser please refer to the references within our Privacy Policy. By using our site you accept the terms of our Privacy Policy.Yes I agree to this